Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASPIRE: Buloxibutid in Idiopathic Pulmonary Fibrosis
NCT06588686Phase 2Active, not recruiting
- Sponsor
- Vicore Pharma
- Start
- Dec 2024
- Primary completion
- May 2027
- Modality
- Small Molecules
- Countries
- 14
01
Overview
Phase 2, randomised, double-blind trial of buloxibutid in idiopathic pulmonary fibrosis (IPF) (3 arms), sponsored by Vicore Pharma. Primary endpoint: Forced Vital Capacity at 52 weeks. Started Dec 2024; status: active, not recruiting.
02
Drugs
buloxibutid
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT06588686.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06588686.